SCHEMBL21777833

SCHEMBL21777833

NCc1c(F)ccc(F)c1CN1CCCC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
HTT P42858 1/20 0.49
PRMT6 Q96LA8 2/20 0.44
GRIN2B Q13224 3/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
KDM4E B2RXH2 4/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HRH3 Q9Y5N1 2/20 0.42
POLB P06746 1/20 0.41
TSHR P16473 1/20 0.41
CYP2A13 Q16696 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HRH4 Q9H3N8 1/20 0.38
CA2 P00918 1/20 0.38
NCF1 P14598 1/20 0.38
CHKA P35790 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20237959 0.96 ALDH1A1 (0.44) ALDH1A1HTTPRMT6GRIN2BCYP1A2
SCHEMBL29668993 0.96 ALDH1A1 (0.44) ALDH1A1HTTPRMT6GRIN2BCYP1A2
SCHEMBL29669033 0.84 CYP2A13 (0.48) ALDH1A1HTTPRMT6KDM4ESMN1; SMN2
SCHEMBL20238899 0.84 CYP2A13 (0.48) ALDH1A1HTTPRMT6KDM4ESMN1; SMN2
SCHEMBL20472427 0.79 ALDH1A1 (0.57) ALDH1A1HTTPRMT6GRIN2BCYP1A2
SCHEMBL20237531 0.79 ALDH1A1 (0.62) ALDH1A1PRMT6KDM4ESMN1; SMN2POLB
SCHEMBL29786443 0.79 ALDH1A1 (0.57) ALDH1A1HTTPRMT6GRIN2BCYP1A2
SCHEMBL29668760 0.79 ALDH1A1 (0.62) ALDH1A1PRMT6KDM4ESMN1; SMN2POLB
SCHEMBL10211855 0.78 ALDH1A1 (0.62) ALDH1A1HTTGRIN2BCYP1A2CYP2D6
SCHEMBL20256796 0.78 ALDH1A1 (0.65) ALDH1A1HTTPRMT6CYP2D6KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112638879-B Heteroaryl substituted sulfonamide compounds and their use as therapeutic agents 泽农医药公司 2024-06-18 CN disclosed
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. 2023-05-02 US disclosed
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. 2023-05-02 US disclosed
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. 2023-05-02 US disclosed
US-20220348570-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2022-11-03 US disclosed
EP-3844150-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS Xenon Pharmaceuticals Inc. (CA) 2021-07-07 EP disclosed
US-10981905-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-04-20 US disclosed
US-10981905-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-04-20 US disclosed
US-20200157089-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-05-21 US disclosed
US-20200157089-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-05-21 US disclosed
WO-2020047323-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 WO disclosed
WO-2020047323-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents SCN1A, SCN2A, SCN2B ALDH1A1 2781/4885HTT 375/4885PRMT6 4563/4885
US-20200157089-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN2A, SCN2B ALDH1A1 2781/4885HTT 375/4885PRMT6 4563/4885
US-10981905-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents SCN1A, SCN2A, SCN2B ALDH1A1 2781/4885HTT 375/4885PRMT6 4563/4885
US-20220348570-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN2A, SCN2B ALDH1A1 2781/4885HTT 375/4885PRMT6 4563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.